Publikace
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart2018 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite2017 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products2016 | Farmaceutická fakulta v Hradci Králové
- Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury2016 | Farmaceutická fakulta v Hradci Králové
- Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites2015 | Farmaceutická fakulta v Hradci Králové
- Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs2014 | Farmaceutická fakulta v Hradci Králové
- Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury2014 | Farmaceutická fakulta v Hradci Králové
Loading network view...